Explore the Agenda
8:30 am Check in & Light Refreshments
Morning Workshop
9:30 am Evaluating Isotopes: Understanding the Effects of Alpha, Beta & Auger Emitters on Different Tumor Types to Optimize Matching with Your Targeting Molecule for Maximum Therapeutic Impact
This workshop will explore the latest advances in alpha, beta, and Auger emitters for targeted radiopharmaceutical therapy, highlighting isotopes such as actinium-225, lead-212, lutetium-177, terbium-161, radium-223, and iodine-125. Join your peers to examine how their unique radiation properties – range, energy, and DNA damage – can be leveraged to maximize tumor cell killing while minimizing salivary gland and kidney toxicity. Join this session to discover emerging isotopes that could expand the reach of radioligand therapy and enable treatment of tumors previously considered difficult or heterogeneous.
Discussion Points:
- Are you trying to get a bystander effect? If so, what isotope is best to choose to improve overall therapeutic efficacy?
- Alpha VS Beta emitters – Why move towards Alpha emitters when Beta emitters are more established?
- Why pick particular isotopes for particular targets? How to optimize this match for maximized on-target delivery and minimized off-target effects?
- Considering matching time on target with your isotope – how long before you deposit your dose?
- Considering daughter products that might emerge after initial isotope breakdown?
12:30 pm Lunch Break & Networking
Afternoon Workshop
1:30 pm Two-Pronged Approach: Rationalizing Combinations for Radiotherapy for Increased Efficacy & Synergistic Effects, Ultimately Improving Patient Outcome Through Rational Drug Design
It is widely considered that combination treatment is a cornerstone of cancer therapy. Therefore, this workshop will examine strategies for rational combination approaches in radioligand therapy to maximize therapeutic efficacy while minimizing toxicity. We will explore the biological rationale for pairing RLT with DDR inhibitors, immune checkpoint inhibitors, and emerging immunotherapies, including CAR-T cells. By leveraging the unique DNA-damaging properties of alpha and beta emitters, alongside agents such as DDR inhibitors, we can enhance tumor susceptibility and exploit synergistic mechanisms that amplify tumor cell killing beyond monotherapy. Join this session to guide optimal combination strategies and improve patient outcomes.
Discussion Points:
- How to minimize toxicity whilst also minimizing radiopharmaceutical dose – but
- improve efficacy?
- Establishing the timings of combination therapies – preclinical strategies to understand optimal combination partners
- Overcoming tumor resistance and sensitizing tumors to treatment
- Biomarker-driven patient selection – choosing patients most likely to benefit from specific RLT combinations